Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Benkert

Showing results (51-60 of 171) with videos related to

Pageof 18
Sort By:
Der Nervenarzt|January 5, 2002
[Which properties make a neuroleptic "atypical"?]G Gründer, I Vernaleken, O Benkert
Pharmacopsychiatry|January 1, 1990
B-HT 920--a novel dopamine autoreceptor agonist in the treatment of patients with schizophreniaK Wiedemann, O Benkert, F Holsboer
The Journal of Clinical Endocrinology and Metabolism|May 1, 1977
Stimulation of growth hormone secretion by desimipramin and chlorimipramin in manG Laakmann, G Schumacher, O Benkert
Pharmacopsychiatry|November 1, 1988
Benzodiazepines for catatonic symptoms, stupor, and mutismH Wetzel, I Heuser, O Benkert
Human Psychopharmacology|October 31, 2002
An overview of the clinical efficacy of mirtazapineO Benkert, M Muller, A Szegedi
Psychiatry Research|February 1, 1987
Dissociation of REM sleep and nocturnal penile tumescence in volunteers treated with brofaremineA Steiger, F Holsboer, O Benkert
The Journal of Nervous and Mental Disease|April 1, 1987
Stupor and affective state: alleviation of psychomotor disturbances by lorazepam and recurrence of symptoms after Ro 15-1788H Wetzel, I Heuser, O Benkert
The Journal of Clinical Psychiatry|October 13, 2000
Mirtazapine compared with paroxetine in major depressionO Benkert, A Szegedi, R Kohnen
Lancet (London, England)|November 9, 1974
Letter: Comparison of T.R.H., L.H.-R.H., and placebo in depressionO Benkert, D Martschke, A Gordon
International Clinical Psychopharmacology|September 1, 1996
Minimum effective dose for antidepressants--an obligatory requirement for antidepressant drug evaluation?O Benkert, A Szegedi, H Wetzel
Pageof 18

Showing results (51-60 of 171) with videos related to

Sort By:
Pageof 18
Der Nervenarzt|January 5, 2002
[Which properties make a neuroleptic "atypical"?]G Gründer, I Vernaleken, O Benkert
Pharmacopsychiatry|January 1, 1990
B-HT 920--a novel dopamine autoreceptor agonist in the treatment of patients with schizophreniaK Wiedemann, O Benkert, F Holsboer
The Journal of Clinical Endocrinology and Metabolism|May 1, 1977
Stimulation of growth hormone secretion by desimipramin and chlorimipramin in manG Laakmann, G Schumacher, O Benkert
Pharmacopsychiatry|November 1, 1988
Benzodiazepines for catatonic symptoms, stupor, and mutismH Wetzel, I Heuser, O Benkert
Human Psychopharmacology|October 31, 2002
An overview of the clinical efficacy of mirtazapineO Benkert, M Muller, A Szegedi
Psychiatry Research|February 1, 1987
Dissociation of REM sleep and nocturnal penile tumescence in volunteers treated with brofaremineA Steiger, F Holsboer, O Benkert
The Journal of Nervous and Mental Disease|April 1, 1987
Stupor and affective state: alleviation of psychomotor disturbances by lorazepam and recurrence of symptoms after Ro 15-1788H Wetzel, I Heuser, O Benkert
The Journal of Clinical Psychiatry|October 13, 2000
Mirtazapine compared with paroxetine in major depressionO Benkert, A Szegedi, R Kohnen
Lancet (London, England)|November 9, 1974
Letter: Comparison of T.R.H., L.H.-R.H., and placebo in depressionO Benkert, D Martschke, A Gordon
International Clinical Psychopharmacology|September 1, 1996
Minimum effective dose for antidepressants--an obligatory requirement for antidepressant drug evaluation?O Benkert, A Szegedi, H Wetzel
Pageof 18